<DOC>
	<DOC>NCT02441218</DOC>
	<brief_summary>The primary objective of this study is to demonstrate the superiority of ivabradine over placebo in the reduction of cardiovascular mortality or hospitalisation for worsening heart failure in patients with moderate to severe symptoms of chronic heart failure, a reduced left ventricular ejection fraction and currently receiving recommended therapy for this disease.</brief_summary>
	<brief_title>Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Symptomatic Chronic heart failure (NYHA II, III or IV) Left ventricular systolic dysfunction (LVEF ≤ 35%) Sinus rhythm and resting heart rate ≥ 70 bpm Optimal and unchanged CHF medications or dosages Unstable condition within previous 4 weeks Myocardial infarction or coronary revascularisation within previous 2 months Stroke or transient cerebral ischaemia within previous 4 weeks Congenital heart disease Severe valvular disease Active myocarditis Permanent atrial fibrillation or flutter</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>